IF 4.4 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Alexander Byer-Alcorace, Cody Thomas, Mitchell E Taub, Stephanie Piekos
{"title":"Improved clearance predictions for aldehyde oxidase substrates using a novel triculture human hepatocyte model.","authors":"Alexander Byer-Alcorace, Cody Thomas, Mitchell E Taub, Stephanie Piekos","doi":"10.1016/j.dmd.2025.100051","DOIUrl":null,"url":null,"abstract":"<p><p>Over the last several decades, efforts in medicinal chemistry have aimed to reduce the extent of CYP metabolism of new chemical entities. This approach, however, has led to increased susceptibility to metabolism by non-CYP-mediated pathways, particularly involving other phase I enzymes such as aldehyde oxidase (AO). Commonly used in vitro models, such as suspended or cocultured primary human hepatocytes, have limitations in evaluating the disposition of compounds metabolized by AO due to low or variable levels of enzyme activity. Thus, an in vitro model that exhibits high to moderate levels of AO activity that can better predict the contribution of AO to drug metabolism and its impact on drug clearance is needed. A novel, 2D+ primary human hepatocyte model, TruVivo, was evaluated for its potential utility to improve hepatic clearance (CL<sub>h</sub>) predictions and determine the contribution of AO to drug metabolism in humans. TruVivo demonstrated stable levels of AO activity for at least 2 weeks that were higher than levels in other hepatocyte models. CL<sub>h</sub> predictions generated using TruVivo for the reference compounds carbazeran, zoniporide, zaleplon, and O6-benzylguanine were within 2-fold of reported in vivo CL values. Furthermore, the estimated fraction metabolized by AO for zaleplon and zoniporide was within 25% of reported in vivo values, whereas that for carbazeran and O6-benzylguanine was similar to those generated in other systems. These findings suggest TruVivo may offer a novel means to assess CL<sub>h</sub> of AO substrates more accurately, even over extended incubation times for low clearance compounds. SIGNIFICANCE STATEMENT: The TruVivo in vitro primary human hepatocyte model maintains high levels of aldehyde oxidase (AO) activity for at least 14 days in culture, making the system suitable for evaluating slowly metabolized compounds, particularly those metabolized by AO. This novel system may therefore be useful for improving human clearance predictions for AO substrates.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":"53 4","pages":"100051"},"PeriodicalIF":4.4000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism and Disposition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.dmd.2025.100051","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

过去几十年来,药物化学领域一直在努力降低新化学实体的 CYP 代谢程度。然而,这种方法却增加了非 CYP 介导途径代谢的敏感性,尤其是涉及醛氧化酶(AO)等其他 I 期酶的代谢。常用的体外模型,如悬浮或共培养的原代人类肝细胞,由于酶活性较低或水平不一,在评估由 AO 代谢的化合物的处置方面存在局限性。因此,我们需要一种具有高到中等水平 AO 活性的体外模型,它能更好地预测 AO 对药物代谢的贡献及其对药物清除率的影响。我们对新型 2D+ 原始人类肝细胞模型 TruVivo 进行了评估,以确定其在改善肝清除率(CLh)预测和确定 AO 对人类药物代谢的贡献方面的潜在用途。TruVivo 至少在 2 周内表现出稳定的 AO 活性水平,高于其他肝细胞模型的水平。使用 TruVivo 生成的参考化合物卡巴折伦、唑尼哌利特、扎来普隆和 O6-苄基鸟嘌呤的 CLh 预测值是报告的体内 CL 值的 2 倍以内。此外,经 AO 代谢的扎来普隆和唑尼哌啶的估计部分在报告的体内值的 25% 以内,而卡巴泽兰和 O6-苄基鸟嘌呤的估计部分则与在其他系统中生成的值相似。这些研究结果表明,TruVivo 可以提供一种新的方法来更准确地评估 AO 底物的 CLh,即使对清除率低的化合物而言,也可以延长孵育时间。意义声明:TruVivo 体外原代人类肝细胞模型在培养至少 14 天后仍能保持高水平的醛氧化酶 (AO) 活性,因此该系统适用于评估缓慢代谢的化合物,尤其是经 AO 代谢的化合物。因此,这种新型系统可能有助于提高人体对 AO 底物的清除率预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Improved clearance predictions for aldehyde oxidase substrates using a novel triculture human hepatocyte model.

Over the last several decades, efforts in medicinal chemistry have aimed to reduce the extent of CYP metabolism of new chemical entities. This approach, however, has led to increased susceptibility to metabolism by non-CYP-mediated pathways, particularly involving other phase I enzymes such as aldehyde oxidase (AO). Commonly used in vitro models, such as suspended or cocultured primary human hepatocytes, have limitations in evaluating the disposition of compounds metabolized by AO due to low or variable levels of enzyme activity. Thus, an in vitro model that exhibits high to moderate levels of AO activity that can better predict the contribution of AO to drug metabolism and its impact on drug clearance is needed. A novel, 2D+ primary human hepatocyte model, TruVivo, was evaluated for its potential utility to improve hepatic clearance (CLh) predictions and determine the contribution of AO to drug metabolism in humans. TruVivo demonstrated stable levels of AO activity for at least 2 weeks that were higher than levels in other hepatocyte models. CLh predictions generated using TruVivo for the reference compounds carbazeran, zoniporide, zaleplon, and O6-benzylguanine were within 2-fold of reported in vivo CL values. Furthermore, the estimated fraction metabolized by AO for zaleplon and zoniporide was within 25% of reported in vivo values, whereas that for carbazeran and O6-benzylguanine was similar to those generated in other systems. These findings suggest TruVivo may offer a novel means to assess CLh of AO substrates more accurately, even over extended incubation times for low clearance compounds. SIGNIFICANCE STATEMENT: The TruVivo in vitro primary human hepatocyte model maintains high levels of aldehyde oxidase (AO) activity for at least 14 days in culture, making the system suitable for evaluating slowly metabolized compounds, particularly those metabolized by AO. This novel system may therefore be useful for improving human clearance predictions for AO substrates.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.50
自引率
12.80%
发文量
128
审稿时长
3 months
期刊介绍: An important reference for all pharmacology and toxicology departments, DMD is also a valuable resource for medicinal chemists involved in drug design and biochemists with an interest in drug metabolism, expression of drug metabolizing enzymes, and regulation of drug metabolizing enzyme gene expression. Articles provide experimental results from in vitro and in vivo systems that bring you significant and original information on metabolism and disposition of endogenous and exogenous compounds, including pharmacologic agents and environmental chemicals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信